Danaher Nears $10 Billion Acquisition of Masimo
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy DHR?
Source: seekingalpha
- Acquisition Nearing: Danaher (DHR) is nearing a roughly $10 billion deal to acquire U.S. medical technology firm Masimo (MASI), with an announcement possible as early as Tuesday, which would significantly enhance Danaher's market position in the medical technology sector.
- Premium Valuation: The deal value represents a premium over Masimo's nearly $7 billion market capitalization at Friday's close, indicating Danaher's optimistic outlook on Masimo's growth potential and reflecting its expansion strategy in the medical device market.
- Historic Acquisition: If successful, this would mark Danaher's largest acquisition since its $21.4 billion takeover of Cytiva over five years ago, highlighting the company's ongoing investment and consolidation efforts in the biotechnology sector.
- Market Reaction: Despite Masimo's stock declining by 27% over the past year, this acquisition could provide Danaher with new growth momentum, particularly against the backdrop of sustained demand for medical devices.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy DHR?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on DHR
Wall Street analysts forecast DHR stock price to rise
18 Analyst Rating
17 Buy
1 Hold
0 Sell
Strong Buy
Current: 214.940
Low
240.00
Averages
266.18
High
310.00
Current: 214.940
Low
240.00
Averages
266.18
High
310.00
About DHR
Danaher Corporation is a global life sciences and diagnostics innovator. The Company operates through three segments: Biotechnology, Life Sciences and Diagnostics. The Biotechnology segment includes the bioprocessing and discovery and medical businesses and offers a broad range of equipment, consumables and services that are primarily used by customers to advance and accelerate the research, development, manufacture and delivery of biological medicines. The Life Sciences segment offers a broad range of instruments, consumables, services and software that are primarily used by customers to study the basic building blocks of life, including deoxyribonucleic acid (DNA) and ribonucleic acid (RNA), nucleic acid, proteins, metabolites and cells. The Diagnostics segment offers clinical instruments, consumables, software and services that hospitals, physicians’ offices, reference laboratories and other critical care settings use to diagnose disease and make treatment decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Danaher Nears $10 Billion Acquisition of Masimo
- Acquisition Nearing: Danaher (DHR) is nearing a roughly $10 billion deal to acquire U.S. medical technology firm Masimo (MASI), with an announcement possible as early as Tuesday, which would significantly enhance Danaher's market position in the medical technology sector.
- Premium Valuation: The deal value represents a premium over Masimo's nearly $7 billion market capitalization at Friday's close, indicating Danaher's optimistic outlook on Masimo's growth potential and reflecting its expansion strategy in the medical device market.
- Historic Acquisition: If successful, this would mark Danaher's largest acquisition since its $21.4 billion takeover of Cytiva over five years ago, highlighting the company's ongoing investment and consolidation efforts in the biotechnology sector.
- Market Reaction: Despite Masimo's stock declining by 27% over the past year, this acquisition could provide Danaher with new growth momentum, particularly against the backdrop of sustained demand for medical devices.
See More
Masimo Realigns to Focus on Core Healthcare Business
- Core Business Focus: Masimo is undergoing an organizational realignment to sharpen its focus on core healthcare offerings, aiming to enhance market competitiveness and optimize resource allocation, particularly in the medical monitoring sector.
- Patent Litigation Update: A U.S. jury ordered Apple to pay Masimo $634 million in damages for patent infringement, and although Apple is appealing, this ruling could positively impact Masimo's financial outlook.
- Potential Acquisition Deal: Reports indicate that Masimo is nearing a roughly $10 billion buyout by life sciences giant Danaher, which could further strengthen Masimo's market position in the medical technology sector.
- Leadership Changes: Under new CEO Katie Szyman, who took over in February, Masimo has sold its Sound United audio business to better focus on healthcare, reflecting a significant strategic shift for the company.
See More
Investigation into Danaher Corporation's Board Conduct
- Shareholder Rights Investigation: Halper Sadeh LLC is investigating whether certain officers and directors of Danaher Corporation (NYSE: DHR) breached their fiduciary duties to shareholders, potentially impacting corporate governance and shareholder rights.
- Legal Relief Options: Long-term shareholders of Danaher may seek corporate governance reforms, fund returns, or court-approved financial incentive awards, which could enhance management practices and transparency.
- Importance of Shareholder Participation: Shareholder involvement can drive improvements in company policies, practices, and oversight mechanisms, thereby increasing transparency and accountability, ultimately enhancing shareholder value.
- Legal Fee Arrangement: Halper Sadeh LLC will handle the case on a contingent fee basis, meaning shareholders will not be responsible for out-of-pocket legal fees or expenses, thus reducing the financial burden of participation.
See More
Revvity Reports Strong Q4 2025 Earnings, Exceeds Expectations
- Earnings Growth: Revvity reported adjusted earnings of $1.70 per share for Q4 2025, a 19.7% year-over-year increase that surpassed the consensus estimate of $1.55, indicating robust profitability and competitive strength.
- Sales Increase: The company achieved sales of $772.06 million, up 6% year-over-year with 4% organic growth, exceeding the market expectation of $761.29 million, reflecting sustained demand for its products in the market.
- Life Sciences Segment Performance: The Life Sciences segment generated $382 million in revenue, a 2% increase, although academic and government demand declined, the growth from pharma and biotech partially offset this, showcasing the segment's resilience.
- Future Guidance: Revvity forecasts adjusted earnings for fiscal 2026 to be between $5.35 and $5.45 per share, with sales projected at $2.96 billion to $2.99 billion, reflecting a year-over-year growth of 4%-5%, indicating the company's confidence and strategic planning for future market conditions.
See More
S&P 500 Closes Lower on Friday but Gains for the Week
- Divergent Tech Performance: Meta Platforms saw its stock rise nearly 9% after a Wednesday earnings report that exceeded expectations, while Microsoft dropped over 8% due to disappointing cloud business results, indicating a split in market sentiment that could influence future investment strategies.
- Starbucks Stock Volatility: Despite showcasing CEO Brian Niccol's turnaround plan during Wednesday's earnings and Thursday's Investor Day, Starbucks shares fell over 6%, reflecting market concerns about its long-term growth potential, which may impact investor confidence.
- Software Sector Slammed: Salesforce and ServiceNow dropped 7% and 10%, respectively, amid a broader selloff in the software sector, suggesting that the market is compressing valuations for SaaS companies, potentially leading investors to reassess their portfolios.
- Fed Policy Impact: The Federal Reserve's decision to hold interest rates steady on Wednesday, coupled with Trump's nomination of Kevin Warsh to succeed Powell, elicited little market reaction; however, gold and silver prices plummeted due to concerns over future Fed independence, highlighting the potential implications of policy changes.
See More
Mixed Close for US Stocks as Chipmakers Rally
- Chipmaker Strength: ASML reported record Q4 bookings of €13.2 billion, significantly exceeding the consensus of €6.85 billion, which boosted chipmakers and AI infrastructure stocks, enhancing market confidence in AI spending sustainability.
- Fed Policy Unchanged: The FOMC maintained the interest rate at 3.50%-3.75% as expected, with Chair Powell indicating strong economic performance without signaling imminent rate cuts, keeping market focus on future policy directions.
- Dollar and Gold Fluctuations: The dollar index rebounded after hitting a nearly four-year low, while President Trump's comments on dollar weakness pushed gold prices up over 3% to a new all-time high, reflecting increased demand for safe-haven assets.
- Economic Data Expectations: Initial jobless claims are expected to rise by 5,000 to 205,000 this week, and Q3 nonfarm productivity is anticipated to remain at 4.9%, indicating ongoing economic growth and potential market volatility.
See More
Danaher Nears $10 Billion Acquisition of Masimo
- Acquisition Nearing: Danaher (DHR) is nearing a roughly $10 billion deal to acquire U.S. medical technology firm Masimo (MASI), with an announcement possible as early as Tuesday, which would significantly enhance Danaher's market position in the medical technology sector.
- Premium Valuation: The deal value represents a premium over Masimo's nearly $7 billion market capitalization at Friday's close, indicating Danaher's optimistic outlook on Masimo's growth potential and reflecting its expansion strategy in the medical device market.
- Historic Acquisition: If successful, this would mark Danaher's largest acquisition since its $21.4 billion takeover of Cytiva over five years ago, highlighting the company's ongoing investment and consolidation efforts in the biotechnology sector.
- Market Reaction: Despite Masimo's stock declining by 27% over the past year, this acquisition could provide Danaher with new growth momentum, particularly against the backdrop of sustained demand for medical devices.
See More
Masimo Realigns to Focus on Core Healthcare Business
- Core Business Focus: Masimo is undergoing an organizational realignment to sharpen its focus on core healthcare offerings, aiming to enhance market competitiveness and optimize resource allocation, particularly in the medical monitoring sector.
- Patent Litigation Update: A U.S. jury ordered Apple to pay Masimo $634 million in damages for patent infringement, and although Apple is appealing, this ruling could positively impact Masimo's financial outlook.
- Potential Acquisition Deal: Reports indicate that Masimo is nearing a roughly $10 billion buyout by life sciences giant Danaher, which could further strengthen Masimo's market position in the medical technology sector.
- Leadership Changes: Under new CEO Katie Szyman, who took over in February, Masimo has sold its Sound United audio business to better focus on healthcare, reflecting a significant strategic shift for the company.
See More
Investigation into Danaher Corporation's Board Conduct
- Shareholder Rights Investigation: Halper Sadeh LLC is investigating whether certain officers and directors of Danaher Corporation (NYSE: DHR) breached their fiduciary duties to shareholders, potentially impacting corporate governance and shareholder rights.
- Legal Relief Options: Long-term shareholders of Danaher may seek corporate governance reforms, fund returns, or court-approved financial incentive awards, which could enhance management practices and transparency.
- Importance of Shareholder Participation: Shareholder involvement can drive improvements in company policies, practices, and oversight mechanisms, thereby increasing transparency and accountability, ultimately enhancing shareholder value.
- Legal Fee Arrangement: Halper Sadeh LLC will handle the case on a contingent fee basis, meaning shareholders will not be responsible for out-of-pocket legal fees or expenses, thus reducing the financial burden of participation.
See More
Revvity Reports Strong Q4 2025 Earnings, Exceeds Expectations
- Earnings Growth: Revvity reported adjusted earnings of $1.70 per share for Q4 2025, a 19.7% year-over-year increase that surpassed the consensus estimate of $1.55, indicating robust profitability and competitive strength.
- Sales Increase: The company achieved sales of $772.06 million, up 6% year-over-year with 4% organic growth, exceeding the market expectation of $761.29 million, reflecting sustained demand for its products in the market.
- Life Sciences Segment Performance: The Life Sciences segment generated $382 million in revenue, a 2% increase, although academic and government demand declined, the growth from pharma and biotech partially offset this, showcasing the segment's resilience.
- Future Guidance: Revvity forecasts adjusted earnings for fiscal 2026 to be between $5.35 and $5.45 per share, with sales projected at $2.96 billion to $2.99 billion, reflecting a year-over-year growth of 4%-5%, indicating the company's confidence and strategic planning for future market conditions.
See More
S&P 500 Closes Lower on Friday but Gains for the Week
- Divergent Tech Performance: Meta Platforms saw its stock rise nearly 9% after a Wednesday earnings report that exceeded expectations, while Microsoft dropped over 8% due to disappointing cloud business results, indicating a split in market sentiment that could influence future investment strategies.
- Starbucks Stock Volatility: Despite showcasing CEO Brian Niccol's turnaround plan during Wednesday's earnings and Thursday's Investor Day, Starbucks shares fell over 6%, reflecting market concerns about its long-term growth potential, which may impact investor confidence.
- Software Sector Slammed: Salesforce and ServiceNow dropped 7% and 10%, respectively, amid a broader selloff in the software sector, suggesting that the market is compressing valuations for SaaS companies, potentially leading investors to reassess their portfolios.
- Fed Policy Impact: The Federal Reserve's decision to hold interest rates steady on Wednesday, coupled with Trump's nomination of Kevin Warsh to succeed Powell, elicited little market reaction; however, gold and silver prices plummeted due to concerns over future Fed independence, highlighting the potential implications of policy changes.
See More
Mixed Close for US Stocks as Chipmakers Rally
- Chipmaker Strength: ASML reported record Q4 bookings of €13.2 billion, significantly exceeding the consensus of €6.85 billion, which boosted chipmakers and AI infrastructure stocks, enhancing market confidence in AI spending sustainability.
- Fed Policy Unchanged: The FOMC maintained the interest rate at 3.50%-3.75% as expected, with Chair Powell indicating strong economic performance without signaling imminent rate cuts, keeping market focus on future policy directions.
- Dollar and Gold Fluctuations: The dollar index rebounded after hitting a nearly four-year low, while President Trump's comments on dollar weakness pushed gold prices up over 3% to a new all-time high, reflecting increased demand for safe-haven assets.
- Economic Data Expectations: Initial jobless claims are expected to rise by 5,000 to 205,000 this week, and Q3 nonfarm productivity is anticipated to remain at 4.9%, indicating ongoing economic growth and potential market volatility.
See More
